IL-4Rα signaling promotes barrier-altering oncostatin M and IL-6 production in aspirin-exacerbated respiratory disease.
Chongjia C ChenKathleen M BuchheitPui Y LeeKailey E BrodeurAaqib SohailLaura ChoCarolyn H BalohBarbara BalestrieriTahereh DerakhshanChunli FengJoshua A BoyceDaniel F DwyerTanya M LaidlawPublished in: The Journal of allergy and clinical immunology (2024)
In addition to type 2 inflammation, innate and IL-6-related cytokines are also elevated in the respiratory tract in AERD. Both OSM and IL-6 are locally produced in nasal polyps and likely promote pathology by negatively affecting epithelial barrier function. IL-4Rα blockade, although seemingly directed at type 2 inflammation, also decreases mediators of innate inflammation and epithelial dysregulation, which may contribute to dupilumab's therapeutic efficacy in AERD.